MiNK Therapeutics Inc. (INKT) is gearing up for a catalyst-packed 2026, with key milestones on the horizon - from the initiation of trials to new data readouts and multiple scientific presentations.
This clinical-stage biopharmaceutical company is developing innovative allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com